XF-73 | |
---|---|
Identifiers | |
CAS number | 718638-68-7 |
Jmol-3D images | Image 1 |
|
|
Properties | |
Molecular formula | C44H50Cl2N6O2 |
Molar mass | 765.81 g mol−1 |
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
Infobox references |
XF-73 is an experimental drug candidate. It is an anti-microbial which works via weakening bacteria cell walls.[1] It is a potential treatment for methicillin-resistant Staphylococcus aureus (MRSA) and possibly Clostridium difficile. It is being developed by Destiny Pharma Ltd.[2][3][4]
It has completed a phase I clinical trial for nasal decolonisation of MRSA - being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.[1][5]
Structurally it is a dicationic porphyrin.[6]